SCHEMBL2585424

SCHEMBL2585424

CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(-c2ccc(N3CCNCC3)nc2)cc2c1c(C)nn2C(C)C

nearest known ligand 0.80

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
EZH1 Q92800 11/20 0.80
EZH2 Q15910 13/20 0.77
EED O75530 2/20 0.71
SUZ12 Q15022 2/20 0.71
PRMT3 O60678 1/20 0.71
RBBP4 Q09028 1/20 0.71
RBBP7 Q16576 1/20 0.71
AEBP2 Q6ZN18 1/20 0.71
SETD7 Q8WTS6 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12180694 0.93 EZH2 (0.79) EZH1EZH2EEDSUZ12PRMT3
SCHEMBL12180731 0.92 EZH2 (0.88) EZH1EZH2EEDSUZ12RBBP4
Hydrochloric Acid SCHEMBL2590277 0.91 EZH2 (0.87) EZH1EZH2EEDSUZ12RBBP4
SCHEMBL30459645 0.89 EZH1 (1.00) EZH1EZH2EEDSUZ12PRMT3
SCHEMBL2591377 0.89 EZH1 (1.00) EZH1EZH2EEDSUZ12PRMT3
SCHEMBL12180173 0.88 EZH2 (0.86) EZH1EZH2EEDSUZ12PRMT3
SCHEMBL16786353 0.87 EZH2 (1.00) EZH1EZH2EEDSUZ12RBBP4
SCHEMBL2594803 0.86 EZH1 (0.82) EZH1EZH2EEDSUZ12PRMT3
SCHEMBL12180744 0.85 EZH2 (0.60) EZH1EZH2EEDSUZ12PRMT3
SCHEMBL2590359 0.85 EZH2 (0.78) EZH1EZH2EEDSUZ12PRMT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566328-B1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2015-03-04 EP claimed
US-8846935-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2014-09-30 US claimed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 US claimed
US-9018382-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2015-04-28 US disclosed
US-9018382-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2015-04-28 US disclosed
US-9018382-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2015-04-28 US disclosed
EP-2566328-B1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2015-03-04 EP disclosed
EP-2566328-B1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2015-03-04 EP disclosed
US-20140350013-A1 INDAZOLES GLAXOSMITHKLINE LLC 2014-11-27 US disclosed
US-20140350013-A1 INDAZOLES GLAXOSMITHKLINE LLC 2014-11-27 US disclosed
US-20140350013-A1 INDAZOLES GLAXOSMITHKLINE LLC 2014-11-27 US disclosed
US-8846935-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2014-09-30 US disclosed
WO-2013067300-A1 METHOD OF TREATMENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2013-05-10 WO disclosed
WO-2013067300-A1 METHOD OF TREATMENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2013-05-10 WO disclosed
EP-2566328-A1 INDAZOLES GlaxoSmithKline LLC (US) 2013-03-13 EP disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 US disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 US disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 US disclosed
WO-2011140325-A1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 WO disclosed
WO-2011140325-A1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053383-A1 INDAZOLES IDH3A, CYP3A7, IDH3B EZH1 1398/4885EZH2 1599/4885EED 3742/4885
US-20140350013-A1 INDAZOLES IDH3A, CYP3A7, IDH3B EZH1 1398/4885EZH2 1599/4885EED 3742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.